RET

6 EU-approved indications of 3 drugs need a RET result, in 3 tumour types, most of them in thyroid cancer, non-small cell lung cancer and solid tumours, tumour-agnostic.

Approved indications6

DrugBiomarker requirementRegimenSettingConditions
Non-small cell lung cancer2
No sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations
+ platinum-based chemotherapy
1L
metastatic
None
Monotherapy
Any line
advanced
Not previously treated with a RET inhibitor
Thyroid cancer3
Monotherapy
Any line
advanced
Radioactive iodine-refractory (if radioactive iodine is appropriate); aged 2 years and older
Monotherapy
Any line
advanced
Medullary thyroid cancer only; Aged 2 years and older
Vandetanib
Caprelsa
Monotherapy
Any line
advanced
Medullary thyroid cancer only; Aggressive and symptomatic disease; aged 5 years and older
Solid tumours, tumour-agnostic1
Monotherapy
Any line
advanced
Treatment options not targeting RET provide limited clinical benefit, or have been exhausted; Aged 2 years and older

RET by tumour

Label wording6

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Sugemalimab (Cejemly)
    Cejemly in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitising EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations.
  2. Vandetanib (Caprelsa)
    Caprelsa is indicated for the treatment of aggressive and symptomatic Rearranged during Transfection (RET) mutant medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
  3. Selpercatinib (Retsevmo)
    advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
  4. Selpercatinib (Retsevmo)
    advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate).
  5. Selpercatinib (Retsevmo)
    advanced RET-mutant medullary thyroid cancer (MTC).
  6. Selpercatinib (Retsevmo)
    advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1).